What is MBX stock price today?

MBX (Mbx Biosciences Inc) stock is trading at $28.00 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is MBX stock going up or down today?

MBX stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy MBX stock now?

The decision to buy MBX depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is MBX a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for MBX based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is MBX stock overvalued or undervalued?

MBX currently trades at a P/E ratio of 3.65, which may suggest attractive valuation. Our DCF calculator provides intrinsic value estimates to help determine if MBX is fairly priced.

What is MBX's P/E ratio?

MBX has a price-to-earnings (P/E) ratio of 3.65, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is MBX's market cap?

MBX (Mbx Biosciences Inc) has a market capitalization of $1.26 billion, making it a small-cap stock.

What is MBX's price to book ratio?

MBX trades at a price-to-book (P/B) ratio of 3.25, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does MBX pay dividends?

MBX does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is MBX's dividend yield?

MBX does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is MBX stock a good long-term investment?

MBX's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is MBX's revenue growth rate?

Revenue growth data for MBX is available on our dashboard with detailed financial statement analysis.

Profitability metrics for MBX are available on our dashboard with complete income statement analysis.

What are the risks of investing in MBX?

Key risks for MBX include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does MBX compare to its competitors?

Compare MBX to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize MBX's performance and positioning.

What is MBX's stock price target for 2026?

Our AI model provides price targets for MBX based on fundamental analysis: Bull case $36.40 (+30%), Base case $32.20 (+15%), Bear case $25.20 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about MBX?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for MBX. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is MBX's next earnings report?

MBX reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

MBX - Mbx Biosciences Inc

NYSE * Health Care * Biotechnology

$28.00

+$0.00 (+0.00%)

About Mbx Biosciences Inc

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

MBX Key Statistics

Market Cap

$1.26B

P/E Ratio

3.65

P/B Ratio

3.25

EPS

$7.67

Employees

How MBX Compares to Peers

MBX has the lowest P/E ratio in Biotechnology, suggesting it may be the most undervalued

MBX is the smallest among peers, which may offer higher growth potential

P/E Rank

of 6

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
MBX(This stock)	$1.26B	3.7	0%	0.0%	-
AMGNAmgen Inc	$197.41B	25.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$179.99B	21.4	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$119.21B	30.7	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$78.84B	18.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.64B	20.7	-0%	0.1%	vs BIIB

Mbx Biosciences Inc Company Information

Headquarters: Indiana; U.S.A
Website: mbxbio.com
Sector: Health Care
Industry: Biotechnology

MBX - Mbx Biosciences Inc

About Mbx Biosciences Inc

MBX Key Statistics

How MBX Compares to Peers

Mbx Biosciences Inc Company Information

MBX Lician Score

MBX Financial Snowflake

Upcoming Events for MBX